MarketBeatWed, 20 May 2026 18:05:29 GMTBeam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program AdvancesBEAM+1.23%
Seeking AlphaWed, 13 May 2026 13:46:02 GMTBeam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset StoryBEAM+1.23%
Zacks Investment ResearchFri, 08 May 2026 17:11:19 GMTBEAM's Q1 Loss Wider Than Expected, Revenues Beat EstimatesBEAM+1.23%
Zacks Investment ResearchThu, 07 May 2026 13:56:27 GMTBeam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue EstimatesBEAM+1.23%
The Motley FoolSat, 11 Apr 2026 13:20:03 GMTBeam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.BEAM+1.23%
Zacks Investment ResearchThu, 26 Mar 2026 16:10:28 GMTBEAM Eyes Global Expansion of AATD Study After Strong Early DataBEAM+1.23%
Seeking AlphaThu, 26 Mar 2026 02:15:55 GMTBeam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency TranscriptBEAM+1.23%
BenzingaWed, 25 Mar 2026 14:31:56 GMTBeam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein LevelsBEAM+1.23%
Seeking AlphaFri, 27 Feb 2026 14:40:41 GMTBeam Therapeutics: Great Potential, But Patience Is NeededBEAM+1.23%
Zacks Investment ResearchWed, 25 Feb 2026 17:06:12 GMTBEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/YBEAM+1.23%
Seeking AlphaTue, 24 Feb 2026 21:57:55 GMTBeam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call TranscriptBEAM+1.23%
Zacks Investment ResearchTue, 24 Feb 2026 14:51:01 GMTBeam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue EstimatesBEAM+1.23%
